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Abstract
Background: The objective of the present study was to optimize and validate an automated method to assess the total
antioxidant capacity (TAC) in serum of dogs using the cupric reducing antioxidant capacity (CUPRAC) methodology
(TACc) with bathocuproinedisulfonic acid disodium salt as chelating agent, evaluating also possible variations due to the
use of two different automated analyzers. The method is based on the reduction of Cu2+ into Cu1+ by the action of the
non-enzymatic antioxidants that are present in the sample.
Results: Imprecision was low in both apparatus utilized, and the results were linear across serial Trolox and canine serum
samples dilutions. Lipids did not interfere with the assay; however, hemolysis increased the TACc concentrations. When
TACc concentrations were determined in ten healthy (control) dogs and in twelve dogs with inflammatory bowel
disease (IBD), dogs with IBD had lower TACc concentrations when compared with the healthy dogs.
Conclusions: The method validated in this paper is precise, simple, and fast and can be easily adapted to
automated analyzers.
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Background
Oxidative stress is characterized by the inability of en-
dogenous antioxidants to counteract the oxidative dam-
age on biological targets [1, 2]. Antioxidant response
can be monitored by analysis of individual biomarkers
such as α-tocopherol (vitamin E), carotenoids, glutathi-
one peroxidase, selenium, among others, and/or by as-
says that measure the total antioxidant capacity (TAC).
TAC can be measured by direct methods (e.g., Trolox
equivalent antioxidant capacity) [3] that are based on
the ability of inhibiting the oxidation of a chemical sub-
stance, or by indirect methods based on the determin-
ation of the reductive properties of the sample such as
the cupric reducing antioxidant capacity (CUPRAC)
and the ferric reducing ability of plasma (FRAP) [4, 6,
16]. TAC assays provide a global measurement of the
antioxidant capacity of the body, including in some
cases possible in vivo interaction between different an-
tioxidants [5, 6].
In humans, a decrease of TAC values has been re-
ported in several conditions, including metabolic syn-
drome, prediabetes or surgery [7–10]. In dogs, decreased
TAC values have been reported after surgery and when
anaesthetized with isoflurane [11, 12]. Furthermore, in-
creases in this analyte have been described in demodico-
sis, parvoviral enteritis, and lymphoma [13–15].
CUPRAC assay evaluates the capacity of the sample
in reducing the Cu2+ to Cu1+ in the presence of a che-
lating agent. Neocuproine, bathocuproine and bathocu-
proinedisulfonic acid disodium salt are different
chelating agents used for this purpose. This method
has been applied to human serum, food, and plant ex-
tracts [16–19].
To the authors’ knowledge, no CUPRAC assay has been
validated for TAC measurements in canine serum sam-
ples. The objective of the present study was to optimize
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and validate an automated method to assess the TAC in
serum of dogs using the CUPRAC methodology (TACc)
and the bathocuproinedisulfonic acid disodium salt as the
chelating agent. The evaluation was performed using two
different automated analyzers; therefore possible varia-





boxylic acid), potassium chloride (KCl), sodium chloride
(NaCl), potassium phosphate (KH2PO4), bathocuproinedi-
sulfonic acid disodium salt, and copper(II) sulphate (CuSO4)
were obtained from Sigma-Aldrich. Di-sodium hydro-
gen phosphate anhydrous (Na2HPO4) was obtained
from Panreac.
Apparatus
The analyses were performed in the Cobas Mira Plus Bio-
chemical Auto Analyzer (ABX Diagnostic) and in the
Olympus AU400 Automatic Chemistry Analyzer (Olympus
Europe GmbH).
Principle of the assay
The CUPRAC assay is based on the reduction of Cu2+ into
Cu1+ by the action of the non-enzymatic antioxidants pre-
sented in the sample. The oxidant complex, consisted of
Cu2+-bathocuproinedisulfonic acid (Cu2+-BCS) reacts
with the antioxidants of the sample and is reduced to a
Cu1+-bathocuproinedisulfonic acid (Cu1+-BCS), a stable
complex which has a maximum absorbance at 490 nm
[19]. The antioxidant capacity of the sample is assumed to
be equal to the extent of the complex Cu1+-BCS formation
[19]. The assay used for CUPRAC in the present study was
based on the method described by Campos et al. [19] with
some modifications.
Measurement procedure for the Cobas Mira Plus
biochemical auto analyzer
In brief, a 5 μL volume of sample was pipetted. Then,
195 μL of the reagent 1 were added and a first read at
500 nm was taken. Subsequently, 50 μL of the reagent 2
were added to the reaction and incubated at 37 °C during
200 seconds. After incubation, a second read at 500 nm
was taken and the difference between the first and the sec-
ond read was used to calculate the antioxidant capacity of
the sample. Distilled water was used for blanks.
Measurement procedure for the Olympus AU400
automatic chemistry analyzer
An amount of 195 μL of reagent 1 and 5 μL of sample were
pipetted. A first read at 480 nm was taken before the
addition of the second reagent. Then, 50 μL of reagent 2
were added to the mixture and incubated at 37 °C during
280 seconds. A second read at 480 nm was taken and the
difference between the first and the second read was used
for calculation of the antioxidant capacity of the sample.
Distilled water was used instead of sample or standard for
blanks.
Preparation of standards
Trolox solution at a concentration of 2.0, 1.0, 0.5, 0.25,
0.125, 0.0625 and 0.0 mmol/L were used. The results ob-
tained for test samples were compared with a standard
curve obtained with Trolox and were expressed as milli-
moles of Trolox equivalents per liter.
Optimization of reagents concentrations
To adjust the assay for measurements in canine serum,
different concentrations of reagent 1 and reagent 2 were
tested with the standards at different concentrations and
also with different samples in the Cobas Mira Plus bio-
chemical analyzer.
Reagent 1 was prepared at 0.1, 0.25, 1.0 and 1.6 mmol/L
of bathocuproinedisulfonic acid disodium salt in 10 mmol/
L phosphate buffer (pH 7.4) while reagent 2 was prepared
at 0.1, 0.5, and 0.8 mmol/L of CuSO4 in ultrapure water.
The optimal concentrations were selected based on
the production of a higher signal with lower background
and a lower intra-assay imprecision calculated after ana-
lysis of one sample five times in one assay run.
Analytical validation of the assay
For the analytical validation of the CUPRAC assay, im-
precision, accuracy, and sensitivity were evaluated fol-
lowing previously reported protocols [19–22].
Imprecision
Imprecision was expressed as coefficient of variation
(CV) and was calculated as inter- and intra-assay varia-
tions. The CV was calculated as the standard deviation
(SD) divided by the mean value (Xmean) of analyzed rep-
licates x 100 % in the formula CV = (SD x 100 %)/ Xmean.
To determine inter-assay variation, four serum samples
were used. Inter-assay CV was determined by analyzing
the same samples in separate runs performed on five dif-
ferent days. Five aliquots of each serum sample were
stored in plastic vials at −20 °C until analysis. On the day
of analysis, the samples were brought to room temperature
prior to TACc measurement. The intra-assay CV was cal-
culated after analysis of four samples five times in one
assay run. Intra-assay CV tests were performed for all the
different combination of reagents tested, although in the
results only appear the values for the final concentration
selected for the assay.
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Accuracy
The accuracy was evaluated through assessment of linear-
ity and spiking recovery. The linearity was evaluated by
linearity under dilution, then duplicate determinations of
TACc were made of a canine serum diluted at 1/2, 1/4, 1/
8, 1/16 and 1/32 using ultrapure water. Dilution of a Tro-
lox solution (2.0, 1.0, 0.5, 0.25, 0.125, and 0.0625 mmol/L)
was also analyzed. For the spiking recovery, two canine
serum samples with a known TACc concentration were
mixed in different percentages (12.5, 25, 50, 75 and
87.5 %). The percentages of the measured TACc con-
centrations to the expected TACc concentrations were
then calculated.
Sensitivity
The detection limit was calculated on the basis of data
from 20 replicate TACc determinations of ultrapure water
as mean value plus 3 SDs. The lower limit of quantifica-
tion (LLOQ) was calculated based on the lowest TACc
concentration that could be measured within a CV less
than 15 % [20].
Effects of hemolysis and lipemia
In order to examine the effect of hemolysis and lipemia,
serum samples from three dogs were mixed with various
concentrations of hemoglobin and lipids solution, respect-
ively, and TACc was measured [23]. To study the effects of
hemolysis, fresh hemolysate was prepared by the addition
of distilled water to packed, washed canine red blood cells
from one dog, followed by centrifugation to remove cell
debris. The hemoglobin concentration was adjusted to 80,
40, 20, 10, 5, and 0.0 g/L. Ten μL of each concentration
were added to three 90 μL samples of canine serum to
produce test samples with final hemoglobin concentration
of 8, 4, 2, 1, 0.5, and 0.0 g/L, respectively. The 0.0 g/L con-
centration was reached by adding 10 μL of distilled water
to 90 μL of the serum sample. Prepared samples were used
to determine the TACc concentrations.
To investigate the effects of lipemia, a commercial fat
emulsion (Lipofundina 20 %; Braun Medical S.S.) with tri-
glycerides concentration of 200 g/L was serially diluted to
50, 25, 12.5, 6.25,3.125 and 0.0 g/L. Ten μL of each dilu-
tion were added to 90 μL of the serum samples and were
used to determine the TACc concentration. The final con-
centrations of triglycerides in the samples were 5, 2.5,
1.25, 0.625, 0.3125, and 0.0 g/L (10 μL of distilled water
were added to 90 μL of the serum samples).
The TACc measurements to evaluate the effect of
hemolysis and lipemia in the assay were made in the
Olympus AU400.
Clinical validation
TACc levels were determined in healthy (control) dogs and
dogs with inflammatory bowel disease (IBD). The control
samples were from ten (seven males and three females)
clinically healthy dogs of several different breeds aged be-
tween 3 and 8 years old, that were presented for routine
checkups and had normal physical examination. Twelve
dogs with IBD were included in this study. They were four
female and eight male dogs aged between 3 and 8 years
old also of different several breeds. A diagnosis of IBD was
made on the basis of clinical signs (vomiting, diarrhea, and
weight loss) of at least 3 weeks’ duration, and detection of
lymphoplasmacytic inflammation during histologic exam-
ination of duodenal biopsy samples following the criteria
of Ohta et al. [24]. Exclusion of other causes of chronic
gastrointestinal tract signs including urinalysis, abdominal
ultrasound, fecal exam, complete blood count and serum
biochemistry were made [25, 26].
Blood samples of the healthy and diseased dogs were
collected from each via jugular or lateral saphenous
venipuncture into tubes without anticoagulant. Samples
were centrifuged at 3,500 x g for 5 min at 20 °C. The
Fig. 1 Optimization of both reagent concentrations on a Cobas Mira Plus biochemical analyzer. a, Effect of varying concentrations of reagent 1
(▼, 0.1; ○, 0.25; ●, 1.0; □, 1.6 mmol/L) on the calibration curves obtained at a fixed concentration of CuSO4 at 0.5 mmol/L. b, Effect of varying
concentrations of reagent 2 (▼, 0.1; ●, 0.5; □, 0.8 mmol/L) on the calibration curves obtained at a fixed concentration of bathocuproinedisulfonic
acid disodium salt at 0.25 mmol/L
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serum samples were stored in plastic vials at - 20 °C
until analysis.
Statistical analysis
Arithmetic means, medians, intra- and inter-assay CVs
were calculated by use of routine descriptive statistical
procedures and computer software (Excel 2013, Microsoft;
GraphPad Statistics Guide). Linearity under dilution was
investigated by linear regression. To compare the TACc
results from both analyzers a Spearman correlation coeffi-
cient was used. The influence of hemolysis or lipemia on
TACc concentration was investigated by use of 1-way
ANOVA and Dunnett posttests. Interferograms were
prepared to show the differences in TACc concentrations
when hemoglobin or lipids were added. Kolmogorov-
Smirnov’s test was performed to assess normality of data.
Comparison of the TACc concentrations between healthy
dogs and dogs with IBD were made by use of Student’s t
test once a parametric distribution was given. For all tests,
P < 0.05 was considered as statistically significant.
Results
Analytical validation
Results of the optimization of the reagents appear in
Figs. 1 and 2. When concentrations of 0.1 mmol/L of re-
agent number 1 was tested with Trolox, the method lost
its linearity at high Trolox concentrations. The other
concentrations (0.25, 1.0 and 1.6 mmol/L) showed a
similar reaction kinetic, but the background of the reac-
tion increased with increased concentrations. When dif-
ferent concentrations of reagent number 2 were tested
with Trolox, the concentration of 0.1 mmol/L did not
produce a reaction. Concentrations of 0.5 and 0.8 mmol/
L showed a similar reaction kinetic, but when 0.8 mmol/
L was used, the background was higher.
When canine serum samples were tested, higher
values were obtained when the concentrations of re-
agents 1 and 2 were increased (Fig. 2). However, the
background was also higher. Also, when the reagent 2
was set at 0.8 mmol/L, the imprecision of the assay in-
creased (data not shown). Therefore final concentrations
of 0.25 mmol/L bathocuproinedisulfonic acid disodium
Fig. 2 Absorbance obtained of a reagent blank (H2O instead of sample) (▲) and of two different canine serum samples (●, ■) studied with
different reagent 1 (A, 0.25; B, 1.0; C, 1.6 mmol/L) and reagent 2 concentrations (D, 0.5; E, 0.8 mmol/L). When the reagent 1 was tested, the
reagent 2 was fixed at 0.5 mmol/L and when the reagent 2 was tested, the reagent 1 was fixed at 0.25 mmol/L
Table 1 Mean, standard deviation (SD), intra- and inter-assay CVs variation in TACc concentrations of canine serum samples (two
with lower concentration and two with high concentrations) measured in the two apparatus
Apparatus Validation parameter Number of samples Mean (mmol Trolox equiv./L) SD CV (%)
Cobas Mira Plus Intra-assay 2 0.2325 0.004 1.9
2 0.3823 0.007 1.8
Inter-assay 2 0.2254 0.015 6.8
2 0.3766 0.019 5.1
Olympus AU400 Intra-assay 2 0.2623 0.003 1.2
2 0.3999 0.003 0.7
Inter-assay 2 0.2533 0.022 8.6
2 0.3842 0.030 7.8
TACc total antioxidant capacity using the cupric reducing antioxidant capacity methodology and the bathocuproinedisulfonic acid disodium salt, SD standard
deviation, CV coefficient of variation
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salt (reagent 1) and 0.5 mmol/L CuSO4 (reagent 2) were
established as optimal for the assay.
The mean, SD, and the intra- and inter-assay CVs ob-
tained with the CUPRAC assay in the two apparatus are
shown in Table 1. Intra-assay CVs were lower than 2 % in
all cases. The inter-assay CVs were lower than 7 % and
9 % for the Cobas Mira Plus and Olympus AU400,
respectively.
The method showed a high linearity with the Trolox
and with canine serum sample in both apparatus (Fig. 3).
The results of spiking recovery obtained in the Cobas
Mira Plus were between 100 % and 103 % (Table 2), and
in the Olympus AU400 were between 97 % and 101 %
(Table 3).
The assay detection limit in the Cobas Mira Plus and
Olympus AU400 were 0.017 mmol/L (mean ± SD, 0.001 ±
0.005) and 0.003 mmol/L (mean ± SD, 0.0001 ± 0.001), re-
spectively. The lower limit of quantification could not be
determined because the CVs were less than 15 % in all
cases.
Data of the TACc obtained with the Cobas Mira Plus
were significantly correlated with the data obtained in
the Olympus AU400 (r = 0.973, P < 0.001).
Effects of hemolysis and lipemia
Lipids did not interfere withTACc concentrations (Fig. 4a).
The addition of hemoglobin significantly increased the
TACc concentrations, the increase being proportional with
the hemoglobin concentration of the sample (Fig. 4b).
Clinical validation
The TACc results for serum samples in both apparatus
are shown in Table 4. The TACc concentrations in dogs
with IBD were significantly lower than those in healthy
dogs when measured with both apparatus.
Discussion
In this study, an assay for evaluation of TAC by the
CUPRAC method was described and validated for the
first time in serum of dogs. This method is automated
Fig. 3 a and b, Regression lines showing the TACc concentrations in the Cobas Mira Plus with the Trolox solution and canine serum sample,
respectively. c and d, Regression lines showing the linearity of TACc concentrations in the Olympus AU400 with the Trolox solution and canine
serum sample, respectively. Coefficients of determination (R2) are shown
Table 2 Recovery of CUPRAC assay in canine serum samples
evaluated in the Cobas Mira Plus





(%)High TACc Low TACc
100 0 0.3961 0.3961 100
87.5 12.5 0.3753 0.3771 101
75 25 0.3552 0.3581 101
50 50 0.3156 0.3202 102
25 75 0.2760 0.2822 103
0 100 0.2442 0.2442 100
CUPRAC cupric reducing antioxidant capacity using bathocuproinedisulfonic
acid disodium salt. TACc total antioxidant capacity using the cupric reducing
antioxidant capacity methodology and the bathocuproinedisulfonic acid
disodium salt
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and uses bathocuproinedisulfonic acid disodium salt.
The preparation of the reagents and measurement steps
are simpler and faster compared to what has reported
in other CUPRAC assays [16], making easier its appli-
cation on routine analysis. Although in this paper the
description of the assay is for automated analyzers, the
method can be easily adapted to other formats such as
96 microplate well.
The optimal reagent concentrations determined in this
work were different from those described in humans.
Campos et al. [19] reported that the final established con-
centrations were 0.2 and 0.1 mmol/L for reagent number
1 and 2, respectively. Another study reported that the op-
timal concentrations for the reagent number 1 and 2 were
0.7 and 0.128 mmol/L, respectively [27]. In our study, it
was found that higher concentrations of both reagents, es-
pecially reagent 2, were needed for the development of an
optimal reaction (lower background and higher difference
in absorbance between healthy and diseased individuals,
and lower imprecision) in dog serum.
The validation results showed that the method has a
good precision since all the intra- and inter-assay CVs in
both apparatus were lower than 9 %. The method showed
a good linearity with dog samples and with serial dilutions
of Trolox. Campos et al. [19] also reported a linearity of
this assay with Trolox dilutions. The assay showed recov-
ery rates of around 100 % when canine serum samples
were mixed at different proportions, indicating that the
assay was accurate when measuring the TACc in canine
serum samples.
The validation was performed in two different automated
analyzers, the Cobas Mira Plus and Olympus AU400 in
order to evaluate their agreement [28] and the repeatability
of method in different equipment [29]. In this study, a high
correlation between the TACc results obtained using the
Cobas Mira Plus and Olympus AU400 was achieved re-
vealing that this assay can be performed in both apparatus.
Regarding the analytical validation results, the two auto-
mated equipment also gave similar results with the excep-
tion of the detection limit that was higher in the Cobas
Mira Plus compared with the Olympus AU400. However,
both detection limits were lower than the values usually
observed in routine analyses and do not compromise the
analytical sensitivity of the assay.
The presence of lipemia and hemolysis can interfere
with the results of various analytes leading to an erroneous
interpretation if the effect is unknown [23]. In the case of
the CUPRAC assay, the lipemia did not interfere with the
assay, which is an advantage to use it in clinical setting.
However, hemolysis resulted in higher TACc concentra-
tions. Therefore, results of this assay should be interpreted
with caution when hemolytic samples are used.
Dogs with IBD had lower TACc concentrations than
healthy dogs. The IBD is a progressive gastrointestinal tract
disorder of unknown cause [25, 30]. During active episodes
of IBD, the uncontrolled overproduction of reactive oxygen
species could easily overwhelm the antioxidants, which are
protective mechanisms, resulting in oxidative damage to
cells and tissue. It was suggested that, this event may play a
role in the pathogenesis of the disease [31–33]. In humans,
the serum TAC, evaluated by the crocin bleaching method,
was significantly reduced in IBD patients compared to
healthy controls [32]. This is in line with the results of the
present study, where our assay was able to demonstrate
Table 3 Recovery of CUPRAC assay in canine serum samples
evaluated in the Olympus AU400





(%)High TACc Low TACc
100 0 0.2346 0.2346 100
87.5 12.5 0.2571 0.2584 101
75 25 0.2796 0.2785 100
50 50 0.3245 0.3136 97
25 75 0.3695 0.3687 100
0 100 0.4144 0.4144 100
CUPRAC cupric reducing antioxidant capacity using bathocuproinedisulfonic
acid disodium salt. TACc total antioxidant capacity using the cupric reducing
antioxidant capacity methodology and the bathocuproinedisulfonic acid
disodium salt
Fig. 4 Interferogram for the effect of lipids (a) and hemoglobin (b) on TACc concentration. Values for each given concentration (Vf) are reported
as a percentage of the original value (Vo).* Significantly increased (P < 0.05)
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diminished concentrations of total antioxidants likely in re-
sponse to oxidative stress in dogs with IBD.
Conclusions
In conclusion, the automated CUPRAC assay validated
in this study can measure the TAC in serum of dogs in a
simple, fast and reliable manner and could be adapted to
two common automated analyzers. It is expected that
this assay could contribute to a wider use of TACc mea-
surements and therefore the evaluation of the antioxi-
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